GYG Gyg Plc

RNS No 4370d
GYRUS GROUP PLC
14th May 1998                                                            

Contacts:

Mark  Goble,  Gyrus  Group PLC,        0171  638  2232 (today)
                                       01222 300100 (thereafter)
Tim Anderson/Kirsty Swan,
Buchanan Communications               0171 466 5000

          European Launch of Gyrus Endourology System
                               
Gyrus   Group  PLC,  the  PlasmaKinetic  endosurgical   device
company,  announces  the European launch,  at  the  Technology
Investor Exhibition in London, of the Gyrus Endourology System
for  treatment of prostatic enlargement and recurrent  bladder
tumours.

                          Highlights

* The world-wide market in the surgical treatment of prostate
  gland enlargement, known as BPH,  has been estimated at over
  $100million per annum

* Introduction  of  the  Gyrus Endourology  System  on  plan
  achieves another key milestone scheduled during our flotation
  on the London Stock Exchange in November 1997.

* This is the first product to be sold through Gyruss sales
  and  marketing  division established at  a  second  facility
  located in the Thames Valley.

* Combined with  the  VAPRTM  Arthroscopic  System   and
  VersaPointTM Hysteroscopic System sold through our marketing
  alliances with Johnson & Johnson, this represents the  third
  system based on our PlasmaKinetic technology launched in just
  over a year.

Mark Goble, Chief Executive commented:

"We  continue  to  demonstrate  our  ability  to  achieve  the
ambitious  goals  we have set ourselves.   This  milestone  is
particularly significant in that we now have direct access  to
the European market through which we can establish our name as
a  leader in advanced technologies for minimal access and  day
case surgery".

        European Launch of the Gyrus Endourology System

The  Gyrus Endourology system addresses procedure applications
in  the  endoscopic urology market, 80% of which  involve  the
treatment of prostate gland enlargement, known as BPH.  As the
prostate gland surrounds the outlet of the bladder in men, BPH
interferes with or can even obstruct the normal flow of urine.
It  is a common problem, affecting 10% of men over 60 years of
age, often requiring surgical removal of the overgrown part of
the gland. The clinical and economic advantages of the Groups
PlasmaKinetic  technology  are becoming  well  established  in
other  markets; shorter operating time, reducing bleeding  and
faster  recovery.  These advantages are equally applicable  to
endoscopic urological procedures.

In Europe, the Endourology system will be sold through Gyruss
sales  and marketing division established in a second facility
in  the  Thames  Valley.  In the UK, a  sales  team  has  been
recruited  and  in  Spain  regional  distributors  have   been
appointed.  Plans are well advanced in France and distribution
channels  to access other European markets will be added  over
the  next  year.  The Group will also be seeking to  establish
marketing alliances to address the US and Japanese markets.

The  first  phase  of the PlasmaKinetic development  addresses
endoscopic  procedure  applications in  three  major  surgical
specialities;  arthroscopic  treatment  of  sports   injuries,
hysteroscopic  treatment  of  uterine  abnormalities  and   in
endoscopic urology.  The VAPRTM arthroscopic system,  launched
in  April  1997,  is  sold under a world-wide  agreement  with
Johnson & Johnson.  The VersaPointTM hysteroscopic system sold
through  Gynecare,  now  part of  Ethicon  Inc  following  its
acquisition  by  Johnson  &  Johnson  in  November  1997,  was
launched  in  March  1997.   With  the  launch  of  the  Gyrus
Endourology  system,  the  first phase  of  the  PlasmaKinetic
development  strategy is complete, just over a year  following
launch of the first system.

Based  on  radio frequency (RF) energy, Gyruss  PlasmaKinetic
endosurgical technology utilises the conductive properties  of
fluids  used  to  distend the operative  site  during  minimal
access surgical procedures.  The capability of controlling and
adjusting  power  in  microseconds enables  selection  of  two
tissue  effect modes.  In the first mode an ionised plasma  is
created  over the active zone of a tissue treatment electrode.
Tissue  entering the intense kinetic energy of the  plasma  is
instantaneously  vaporised and simply washed  away.   The  low
thermal  mass of the plasma prevents collateral tissue  damage
adjacent to the application site.  In the second mode,  rapid,
predictable  and  controlled elevations in tissue  temperature
can  be  produced to seal blood vessels or modify soft  tissue
structures.

In  January 1998, the Group announced launch of the  VAPRTM  T
range,  two  months ahead o schedule; extending  the  exciting
range  of  applications of the VAPRTM  system by providing  an
arthroscopic  treatment for joint instability.  The  Group  is
currently developing additional products to further expand the
applications  and  versatility of the VAPRTM and  VersaPointTM
systems, as well  as  developing  enhancements to the
PlasmaKinetic technology  to open additional market 
opportunities. These opportunities will  be  addressed  both
through  Gyruss  direct sales and marketing division  and  by
seeking additional corporate alliances in selected 
geographical and speciality-based markets.

END

MSCAOABKWWKVAAR

Gyg (LSE:GYG)
Historical Stock Chart
Von Jun 2024 bis Jul 2024

Gyg (LSE:GYG)
Historical Stock Chart
Von Jul 2023 bis Jul 2024